Reduced B cell activation in Germinal center reaction of the mouse model of Li-Fraumeni syndrome

Abstract

The TP53 mutation associated with Li-Fraumeni syndrome in humans is known to exhibit p53 gain-of-function properties leading to early cancer onset. To explore whether these patients also have compromised immune responses due to p53 mutations, we investigated the humoral immune response using a Li-Fraumeni mouse model harboring a structural mutation, Trp53R172H (equivalent to codon 175 in humans). Trp53R172H mice were immunized with sheep red blood cells, and the Germinal center response was monitored. Our results revealed that SRBC-immunized Trp53R172H mice exhibit reduced B cell activation during the GC reaction. These suggest a selective role for p53 in promoting B cell activation early in the GC reaction prior to BCL6 upregulation. We propose that impaired B cell activation in Li-Fraumeni patients could contribute to immune deficiencies and heightened susceptibility to autoimmune disorders, potentially influencing the development of secondary cancers and impairing therapeutic responses to chemotherapies and immunotherapies. Key PointsO_LITrp52R172H mice exhibit reduced B cell activation during the Germinal center reaction C_LIO_LIRatio of activated B cells in DZ to LZ remain unchanged in Trp52R172H mice. C_LI